We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Just days after the FTC won a temporary injunction to halt IQVIA’s proposed acquisition of Propel Media’s DeepIntent healthcare advertising business, the companies have mutually agreed to abandon the proposed merger. Read More
The FDA has approved Florida’s plan to import drugs from Canada, making it the first state permitted to do so, after submitting its plan to the FDA in 2020. Read More
In an effort to stay dominant in the burgeoning obesity market and expand in the liver disease space, Novo Nordisk has forged two new research partnerships, each potentially worth up to $532 million. Read More
In a move that sidesteps pharmacy benefit managers, Eli Lilly has launched a direct-to-consumer marketing program that will provide several of the company’s medicines for obesity, migraine, and diabetes at steeply discounted prices, and without the need for a face-to-face doctor visit. Read More
A New Jersey judge ruled last week that Teva Pharmaceuticals did not infringe on two Corcept patents for its Cushing’s syndrome drug Korlym (mifepristone). Read More
The FTC won its motion to temporarily block IQVIA’s planned purchase of California health advertising firm Propel Media, deeming further review by the commission would be in the public interest. Read More